

May 9, 2019

H.E. Mr. Victor DOLIDZE
Permanent Mission of Georgia
Rue Richard Wagner 1
Geneva 1202, Switzerland

Your Excellency,

The TB Alliance is a not-for-profit, public-private partnership accelerating the discovery and development of affordable new anti-tuberculosis (TB) regimens that aim to shorten treatment, and be effective against multi-drug resistant strains.

This letter respectfully requests a meeting with appropriate members of the delegation from Georgia visiting Geneva for the World Health Assembly (WHA), with members of TB Alliance leadership attending the Assembly.

The objective of this meeting is to discuss the advances made by TB Alliance in the field of drug-resistant TB, that could be very relevant for the Georgia given the significant burden the disease causes in the country and the region.

TB Alliance has developed a novel drug, pretomanid and an associated drug regimen for the treatment of extensively drug-resistant (XDR) and treatment intolerant/non-responsive multidrug-resistant (MDR) TB. Clinical development has been completed and drug has been filed for registration in the United States and the European Union. The drug regimen has potential to be a simpler, shorter (6 month), all oral treatment, wherein pretomanid is given along with bedaquiline and linezolid (collectively referred to as the BPaL regimen).


We would like to take the opportunity of the WHA to share further details with the delegation, including plans for providing affordable access for the BPaL regimen, and discuss possibilities for introduction of the regimen upon receipt of necessary regulatory approvals.

This is to request assistance of your offices to help set up a meeting with the delegation, or to kindly direct this to the appropriate person at your Mission.

We are available for a meeting during May 20-28, 2019 in Geneva.

I look forward to hearing back and thank you very much for the help and kind consideration.

Sincerely,



Sandeep Juneja
Sr. Vice President – Market Access